Meier Michelle, Mortensen Marie Riis, Larsen Lene Unmack
Department of Surgical Gastroenterology.
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
Cancer Manag Res. 2016 Nov 8;8:129-133. doi: 10.2147/CMAR.S107747. eCollection 2016.
Malignant pleural effusion (MPE) is a disabling condition caused in most instances by far-advanced cancer. The treatment is palliative and should ideally be minimally invasive. The aim of this retrospective study was to evaluate the effectiveness of implantation of a permanent PleurX catheter in the treatment of recurrent MPE in patients with terminal cancer disease.
Eighteen consecutive patients with terminal cancer and MPE, who had a permanent PleurX catheter implanted in the period from February 2014 to August 2015, were retrospectively evaluated. Medical records were reviewed for data on procedures and patients.
Twenty-two PleurX catheters were implanted in the pleural cavity of 18 patients. The technical success rate was 100%. All patients had relief of symptoms. Catheter patency was 91%. Six patients experienced minor adverse events (AEs) and two patients experienced moderate-to-severe AEs. The median survival time for the 14 patients who died during follow-up was 45 days.
Implantation of a permanent PleurX catheter is a safe procedure with a high success rate and only few AEs. The procedure has the potential to serve as an effective procedure for palliation of recurrent MPE in terminal cancer patients.
恶性胸腔积液(MPE)是一种致残性病症,多数情况下由晚期癌症引起。治疗是姑息性的,理想情况下应微创。这项回顾性研究的目的是评估植入永久性PleurX导管治疗晚期癌症患者复发性MPE的有效性。
回顾性评估了2014年2月至2015年8月期间连续18例植入永久性PleurX导管的晚期癌症合并MPE患者。查阅病历以获取手术和患者相关数据。
18例患者的胸腔内共植入22根PleurX导管。技术成功率为100%。所有患者症状均得到缓解。导管通畅率为91%。6例患者出现轻微不良事件(AE),2例患者出现中重度AE。随访期间死亡的14例患者的中位生存时间为45天。
植入永久性PleurX导管是一种安全的手术,成功率高且不良事件极少。该手术有可能成为晚期癌症患者复发性MPE姑息治疗的有效方法。